FDA warned South Korea's Estaderma that its website sells unapproved, misbranded injectable botulinum toxin (Liztox) to U.S. consumers.
What happened
FDA reviewed the website www.estaderma.com and found it offering injectable botulinum toxin type A sold as "Liztox 100u" and "Liztox," promoted for treating excessive sweating. FDA said no approved drug application is in effect for these products and that their labeling lacks adequate directions for use, making them misbranded. Because Estaderma offers them to U.S. consumers, FDA says the drugs are entering interstate commerce illegally.
What FDA found
The company sells a new drug without the FDA approval required before such a drug can be sold in the U.S.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]The product's labeling does not give adequate directions for use, so the drug is misbranded.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]; no exemption under 21 CFR 201.115(a)The company offers a prescription drug for sale to U.S. consumers, putting a misbranded drug into interstate commerce.
FD&C Act sections 301(a) and 503(b) [21 U.S.C. §§ 331(a), 353(b)]Website claims that the product treats excessive sweating show it is a drug intended for human use.
21 CFR 201.128
What FDA wants
FDA asks Estaderma to stop offering any unapproved and misbranded drugs for sale to U.S. consumers, review its websites and labeling, and reply in writing within 15 working days with the steps taken and supporting documents. If corrections cannot be finished in that time, the company must say why and give a completion date.
Who should pay attention
- U.S. aesthetic and dermatology clinics whose patients buy injectables online
- distributors and online sellers of imported botulinum toxin products
- consumers buying discounted wrinkle or sweating injections from foreign websites
This is a summary. Read the original letter on fda.gov.